TY - JOUR
T1 - Programmable On-Chip Artificial Cell Producing Post-Translationally Modified Ubiquitinated Protein
AU - Zilberzwige-Tal, Shai
AU - Levin, Aviad
AU - Toprakcioglu, Zenon
AU - Knowles, Tuomas P.J.
AU - Gazit, Ehud
AU - Elbaz, Johann
N1 - Publisher Copyright:
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2019/8
Y1 - 2019/8
N2 - In nature, intracellular microcompartments have evolved to allow the simultaneous execution of tightly regulated complex processes within a controlled environment. This architecture serves as the blueprint for the construction of a wide array of artificial cells. However, such systems are inadequate in their ability to confine and sequentially control multiple central dogma activities (transcription, translation, and post-translational modifications) resulting in a limited production of complex biomolecules. Here, an artificial cell-on-a-chip comprising hierarchical compartments allowing the processing and transport of products from transcription, translation, and post-translational modifications through connecting channels is designed and fabricated. This platform generates a tightly controlled system, yielding directly a purified modified protein, with the potential to produce proteoform of choice. Using this platform, the full ubiquitinated form of the Parkinson's disease-associated α-synuclein is generated starting from DNA, in a single device. By bringing together all central dogma activities in a single controllable platform, this approach will open up new possibilities for the synthesis of complex targets, will allow to decipher diverse molecular mechanisms in health and disease and to engineer protein-based materials and pharmaceutical agents.
AB - In nature, intracellular microcompartments have evolved to allow the simultaneous execution of tightly regulated complex processes within a controlled environment. This architecture serves as the blueprint for the construction of a wide array of artificial cells. However, such systems are inadequate in their ability to confine and sequentially control multiple central dogma activities (transcription, translation, and post-translational modifications) resulting in a limited production of complex biomolecules. Here, an artificial cell-on-a-chip comprising hierarchical compartments allowing the processing and transport of products from transcription, translation, and post-translational modifications through connecting channels is designed and fabricated. This platform generates a tightly controlled system, yielding directly a purified modified protein, with the potential to produce proteoform of choice. Using this platform, the full ubiquitinated form of the Parkinson's disease-associated α-synuclein is generated starting from DNA, in a single device. By bringing together all central dogma activities in a single controllable platform, this approach will open up new possibilities for the synthesis of complex targets, will allow to decipher diverse molecular mechanisms in health and disease and to engineer protein-based materials and pharmaceutical agents.
KW - aptamers
KW - cell free
KW - microfluidics
KW - post-translation modifications
KW - synthetic biology
UR - http://www.scopus.com/inward/record.url?scp=85067464833&partnerID=8YFLogxK
U2 - 10.1002/smll.201901780
DO - 10.1002/smll.201901780
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:85067464833
SN - 1613-6810
VL - 15
JO - Small
JF - Small
IS - 31
M1 - 1901780
ER -